Interesting to see that during the most recent conference call Inverness spoke about working with Biocurex without mentioning our name directly. I can't help thinking about where this stock would be if Abbott and Inverness would speak about Biocurex as a company instead of a potential new biomarker. Here's an excerpt of the conference call. Read thru till you see what I mean.
* We held a conference call with Ron Zwanziger and Ron
Geraty of Inverness Medical management, focused specifically on the
company's controversial Disease Management strategy.
* Geraty stated clearly that IMA's intention was to offer better, faster, more
convenient, cheaper health care solutions, and Disease Management products/
services that lead to lower mortality rates.
* We found management's enthusiasm and conviction for its Disease Management
offering to be readily apparent, though specifics of the strategy are still
lacking for the most part. As a result, while we believe IMA's strategy is
well thought out, it appears to be coming across to investors as simply a
more ambitious approach to a traditional Disease Management offering rather
than something truly revolutionary, in our view.
* We believe some of this is timing related. IMA management has indicated
repeatedly that it would have preferred to wait at least another year or so
before acquiring Matria, though chose to move early when MATR put the
company up for sale. We believe IMA will be better positioned to show the
true intention of its DM strategy 12 months from now. For example, IMA
management indicated that they are currently rolling out a home rapid
diagnostic program to a selected population of patients with a major client.
In addition, Geraty confirmed that IMA is working with another major client
in a pilot study to test the usefulness of a new biomarker.
From To
Changes (Previous) (Current)
------------------------- ------------------------- -------------------------
Rating -- Buy
Target Price -- $56.00
FY08E EPS (Net) -- $2.03
FY09E EPS (Net) -- $2.80
